|
|
Article: Apthera Secures SPA for Pivotal NeuVax Trial in Breast Cancer.
- Article from:
- BIOWORLD Today
- Article date:
- June 26, 2009
- Author:
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Jennifer Boggs, Assistant Managing Editor
After quietly chugging along amid a swirl of cancer vaccine news, privately held Apthera Inc. popped up on the radar, armed with a special protocol assessment for a pivotal Phase III trial of its peptide-based immunotherapeutic, NeuVax, in early stage breast cancer patients.
The news came only days after fellow cancer vaccine firm Oncothyreon Inc., of Seattle, reported that Stimuvax partner Merck KGaA decided to add a Phase III breast cancer study to its ongoing Phase III study in non-small-cell-lung cancer, signaling a re-energized interest in the space that had been rife with disappointment prior to ...